Exton Michael's Form 4 filing
Lexicon Pharmaceuticals, Inc.LXRX · filed Nov 9, 2026
- Accession no.
- 0001062822-26-000130
- Filed
- Nov 9, 2026, 8:13 AM ET
- Trade date
- Nov 6, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $50.0K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Exton MichaelCIK 0002029249 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Common Stock | PPurchaseAcquired | +30,064 | $1.66F1 | +$49,999.44 | 328,496 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.63 to $1.67 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.